News from ASCO: Could Some Patients Stop Taking Medication for CML?
Jeffrey Lipton discusses news from ASCO 2012 about how Tasigna could bring faster and deeper responses, taking some newly diagnosed patients all the way to Complete Molecular Response (CMR) well within the first year of therapy. Dr. Lipton explains that the focus in Chronic Myelogenous Leukemia (CML) is moving away from simply keeping patients alive and toward the possibility of a cure and being able to discontinue treatment.
Experts & Guests
MD, FRCPC, PhDDr. Jeffrey Lipton is the Head of the Chronic Myeloid Leukemia Program, Princess Margaret Hospital, Ontario Cancer Institute (OCI). He is a member of the Allogeneic Blood and Bone Marrow Transplant Program and the Clinical Studies Resource Centre at OCI. Dr. Lipton's research includes phase I, II and III levels on the therapy of chronic myeloid leukemia. This involves targeted... more >